JNJ director granted 1,540 deferred share units

Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation.

Rhea-AI Filing Summary

Johnson & Johnson director John G. Morikis received a grant of 1,540 Deferred Share Units (DSUs) as compensation. These DSUs were acquired at a stated price of $0.00 per unit and are tied to Johnson & Johnson common stock for value reference.

According to the plan terms, the DSUs will be settled in cash after Morikis’ service as a director ends, with each unit worth the fair market value of one share of common stock on the settlement date. After this grant, he holds 1,540 DSUs related to this plan.

Insider Trade Summary

Grant/Award: 1,540 shares

Grant/Award 1 txn

Insider MORIKIS JOHN G

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	1,540	$0.00	$0.00

Holdings After Transaction: Deferred Share Units — 1,540 contracts (Direct)

Footnotes (1)

1. F1. Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).

Key Figures

Deferred Share Units granted: 1,540 units Price per DSU: $0.00 per unit DSUs outstanding after grant: 1,540 units +1 more

4 metrics

Deferred Share Units granted 1,540 units Grant of DSUs to director on 2026-04-23

Price per DSU $0.00 per unit Stated transaction price for DSU grant

DSUs outstanding after grant 1,540 units Total DSUs held by director following transaction

Underlying common stock reference 1,540 shares Each DSU references one share of common stock

Key Terms

Deferred Share Units, Amended and Restated Deferred Fee Plan for Directors, fair market value, Common Stock

4 terms

Deferred Share Units financial

"Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors"

Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.

Amended and Restated Deferred Fee Plan for Directors financial

"acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors"

fair market value financial

"each DSU representing the fair market value of one share of Common Stock on the settlement date"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

Common Stock financial

"each DSU representing the fair market value of one share of Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Johnson & Johnson (JNJ) director John G. Morikis report on this Form 4?

John G. Morikis reported receiving a grant of 1,540 Deferred Share Units (DSUs) tied to Johnson & Johnson common stock. The units are compensation, not an open-market trade, and are recorded as a derivative-type acquisition on the Form 4.

How many Deferred Share Units did John G. Morikis acquire from Johnson & Johnson (JNJ)?

He acquired 1,540 Deferred Share Units (DSUs) under Johnson & Johnson’s director deferred fee plan. These units track the value of common stock and will be settled in cash based on the fair market value at a future settlement date.

Are the Johnson & Johnson (JNJ) Deferred Share Units granted to Morikis settled in stock or cash?

The Deferred Share Units granted to John G. Morikis are settled in cash. Upon termination of his directorship, each DSU will pay the fair market value of one Johnson & Johnson common share on the settlement date, rather than delivering actual shares.

Did John G. Morikis buy or sell Johnson & Johnson (JNJ) stock in the market in this filing?

No, the filing shows a grant of Deferred Share Units as director compensation, not a market purchase or sale. The DSUs are cash-settled and reference Johnson & Johnson common stock value at a future settlement date.

What is the exercise or conversion price for the Johnson & Johnson (JNJ) Deferred Share Units granted?

The Deferred Share Units in this filing show a conversion or exercise price of $0.00 per unit. They are compensation units under a director deferred fee plan, designed to be settled in cash based on future common stock fair market value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 06:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MORIKIS JOHN G

(Last) (First) (Middle)

ONE JOHNSON & JOHNSON PLAZA

(Street)

NEW BRUNSWICK NEW JERSEY 08933

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
JOHNSON & JOHNSON [ JNJ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	04/23/2026		A		1,540		(1)	(1)	Common Stock	1,540	$0	1,540	D

Explanation of Responses:

1. Grant of Deferred Share Units (DSU) acquired under the Issuer's Amended and Restated Deferred Fee Plan for Directors are to be settled in cash upon termination of the Reporting Person's directorship (with each DSU representing the fair market value of one share of Common Stock on the settlement date).

Remarks:

	/s/ Joleen Morgan, as attorney-in-fact for John Morikis	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)